Healio Rheumatology Current Issue

The following articles appeared in the print edition of Healio Rheumatology.

Table of Contents

• Combined clinics for psoriatic disease leverage expertise 'from two ends of the spectrum' Rebecca L. Forand
• Pediatric rheumatology comes up short on Match Day: Just 69% of fellowship slots filled Jason Laday
• COVID-19, epistemic chaos and rheumatology: How can we critically appraise the science? Leonard H. Calabrese, DO
• FDA approves Rinvoq for patients with active psoriatic arthritis Robert Stott
• FDA approves Xeljanz for active ankylosing spondylitis Jason Laday
• FDA authorizes AstraZeneca antibody cocktail for pre-exposure prevention of COVID-19 Jason Laday
• Hooked on Rheum with S. Louis Bridges, MD, PhD S. Louis Bridges, MD, PhD
• Belimumab after rituximab reduces IgG anti-dsDNA antibody levels, flare risk in lupus Jason Laday
• Colchicine fails to reduce COVID-19 severity, risk for death Jason Laday
• COVID-19 pandemic led to fewer initial rheumatology visits, autoimmunity lab tests Jason Laday
• Health care spending in the US topped $4 trillion in 2020, CMS says Janel Miller
• Hydroxychloroquine prescribers 'should be vigilant' for potential cardiac toxicity Jason Laday
• Fewer than 20% of adults with arthritis attend self-management classes Jason Laday
• Artificial neural network accurately detects sacroiliitis in suspected axial SpA Jason Laday
• Avacopan bests prednisone for kidney function recovery in ANCA vasculitis Rob Volansky
• Booster augments COVID-19 vaccine response in patients on rituximab despite prior failures Rob Volansky
• Breakthrough COVID-19 infection risk highest in RA, gout, polydermatomyositis, vasculitis Rob Volansky
• Disparities in telehealth use for rheumatology linked to language, race, age, income Jason Laday
• Fear of side effects, rheumatic disease flare top reasons for COVID-19 vaccine hesitancy Jason Laday
• Higher dosing, duration of use intensifies risk for hydroxychloroquine retinopathy Jason Laday
• 'Just 30 days of glucocorticoid use' in RA spikes cardiovascular risk by 15% over 6 months Jason Laday
• More than half of patients with rheumatic disease, COVID-19 report 'long-haul' symptoms Jason Laday
• Rate of major cardiovascular events in RA higher for tofacitinib vs. TNF inhibitors Jason Laday
• TULIP: Anifrolumab superior to standard of care for lupus regardless of prior biologic use Robert Stott
• ‘Who do they call?’: Patient, provider education crucial for managing outpatient COVID-19 Rob Volansky
• Platelet inhibitors linked to lower risk for digital ulcers in systemic sclerosis Stacey L. Adams
• Bedside to 'Webside': Telehealth training for rheumatology fellows could bridge care gaps Rob Volansky
• ACIP recommends mRNA vaccines over J&J vaccine Richard Gawel
• Final analysis confirms efficacy of Pfizer’s COVID-19 antiviral Ken Downey Jr.